You are here: Industry Insights > Psoriasis

News List

Psoriasis Patients Often Use CAMs When Traditional Meds Fail drugs
June 28, 2019
Psoriasis Patients Often Use CAMs When Traditional Meds Fail.
NICE approves 3 drugs for treating plaque psoriasis in children europeanpharmaceuticalreview
May 07, 2019
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children…
AbbVie expands immunology portfolio in the U.S. with FDA approval of SKYRIZI™ biospectrumasia
April 28, 2019
AbbVie recently received approval of SKYRIZI from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis
FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults drugs
April 28, 2019
FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults.
FDA Approves of SKYRIZI™ for Moderate to Severe Plaque Psoriasis americanpharmaceuticalreview
April 26, 2019
AbbVie announced the U.S. Food and Drug Administration (FDA) approved SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults...
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis drugs
April 25, 2019
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis.
Skyrizi gets US approval for psoriasis pharmatimes
April 24, 2019
AbbVie has announced the US Food and Drug Administration (FDA) approval of its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis.
Alvotech, Fuji Pharma Sign Commercialization Agreement contractpharma
April 15, 2019
For the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara) in Japan...
FDA Approves Novel TREMFYA One-Press Patient-Controlled Injector americanpharmaceuticalreview
February 28, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved TREMFYA® One-Press....
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis fiercepharma
January 13, 2019
Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page